Silvio Garattini | |
---|---|
Born | |
Nationality | Italian |
Occupation | Physician, chemist, researcher in the field of pharmacology, professor of chemotherapy, director of the Mario Negri Institute for Pharmacological Research |
Years active | 1963 to date |
Employer | Mario Negri Institute for Pharmacological Research |
Parent(s) |
|
Awards | Knight of the Order of Merit of the Italian Republic |
Website | www.marionegri.it |
Silvio Garattini (born in Bergamo November 12, 1928) is an Italian scientist, pharmacology research scientist, physician and professor in chemotherapy and pharmacology and director of the Mario Negri Institute for Pharmacological Research. [1]
Chemical technical specialist and medical doctor, he began his career as an assistant at the Pharmacology Institute [2] of the University of Milan where he remained until 1962 as a senior lecturer in pharmacology and chemotherapy. [3]
In 1963 he founded the Mario Negri Institute for Pharmacological Research of which he became the first director. [3] Over the years, the institute developed to reach staffing of approximately 850 researchers over four different locations in Milan, Bergamo, Ranica and Santa Maria Imbaro. [4]
From 1965 to 1968 he chaired the European Organisation for Research and Treatment of Cancer (EORTC); he is a component of the "Group 2003", [5] a group of Italian researchers held in high esteem in the global pharmaceutical environment. [6]
Garattini is the author of hundreds of publications in international journals and author of several treatises on pharmacology. [3]
During his career he was a member of several national and international organizations, [7] among which are the Committee of Biology and Medicine of the National Research Council (CNR), the Italian National Health Council and the Council of Ministers of the Presidency Commission for research policy in Italy, as well as Member of the Single Commission of the drug (CUF) of Italian Ministry of Health.
Other positions he held include: [8]
He is a fellow of the New York Academy of Sciences, of the American Association for the Advancement of Science and emeritus fellow of the Royal College of Physicians [10] }.
During his long career he received numerous national and international honours, including: the Legion of Honour of the French Republic for scientific merits, Grand Official of Italian Republic and several honorary degrees from several European universities. He received the America Award of the Italy-USA Foundation in 2018.
In 1996 he was criticized by supporters of the Di Bella method because he denied, as a member of the CUF (single commission of the drug), moving somatostatin from the H band to a group A drug which would have provided for the free supply of the drug. This was due to the lack of scientific proof of its effectiveness. [11] He is also criticized by the animalist movements for his favourable position towards animal testing and for having responded to their accusations of gratuitous violence on animals "animal testing is irreplaceable and necessary. Those opposed will have to assume their responsibilities for care and drugs that will not be found. Research cannot be stopped". [12] [13]
- Commanders of the Order of Merit of the Italian Republic - Awarded on December 27, 1990. [14]
- Grand Officer Order of Merit of the Italian Republic - Awarded on December 27, 2005. [15]
- Gold Medal awarded on February 1, 2010. [16]
- Knight of Legion of Honour on 1984. [17]
Honoris Causa from Autonomous University of Barcelona in 1982. [18]
Honoris Causa from University of Białystok in 1984 [19]
Daniel Bovet was a Swiss-born Italian pharmacologist who won the 1957 Nobel Prize in Physiology or Medicine for his discovery of drugs that block the actions of specific neurotransmitters. He is best known for his discovery in 1937 of antihistamines, which block the neurotransmitter histamine and are used in allergy medication. His other research included work on chemotherapy, sulfa drugs, the sympathetic nervous system, the pharmacology of curare, and other neuropharmacological interests.
The European Organisation for Research and Treatment of Cancer (EORTC) is a unique pan-European non-profit clinical cancer research organisation established in 1962 operating as an international association under Belgium law. It develops, conducts, coordinates and stimulates high-quality translational and clinical trial research to improve the survival and quality of life of cancer patients. This is achieved through the development of new drugs and other innovative approaches, and the testing of more effective therapeutic strategies, using currently approved drugs, surgery and/or radiotherapy in clinical trials conducted under the auspices of a vast network of clinical cancer researchers supported by 220 staff members based in Brussels. The EORTC has the expertise to conduct large and complex trials especially specific populations such as the older patient and rare tumours.
CICAP is an Italian, non-profit, skeptic educational organization, founded in 1989. CICAP's main goal is to promote a scientific and critical investigation of pseudosciences, the paranormal, the mysteries and the unusual, with the aim of spreading the scientific attitude and critical thinking.
Luigi Di Bella was an Italian medical doctor and physiology professor. In the late 1980s, he created a purported treatment known as "Di Bella therapy" for cancer that precipitated an international controversy.
Virgil Craig Jordan,, is a scientist with American and British citizenship specializing in drugs for breast cancer treatment and prevention. Currently, he is Professor of Breast Medical Oncology, and Professor of Molecular and Cellular Oncology at the University of Texas MD Anderson Cancer Center, Houston, Texas. Previously, he was Scientific Director and Vice Chairman of Oncology at the Lombardi Comprehensive Cancer Center of Georgetown University. Jordan was the first to discover the breast cancer prevention properties of tamoxifen and the scientific principles for adjuvant therapy with antihormones. More recently his work has branched out into the prevention of multiple diseases in women with the discovery of the drug group, selective estrogen receptor modulator (SERMs). Currently, he plans to develop a new Hormone Replacement Therapy (HRT) for post-menopausal women that prevents breast cancer and does not increase the risk of breast cancer.
John Gordon McVie was an international authority on the treatment and research of cancer. He wrote over 350 peer-reviewed articles, editorials and books. McVie was born in Glasgow, Scotland and died of non-Hodgkin lymphona and COVID-19 in Bristol, England.
Francesco Bellini, is an Italian-born research scientist, administrator, entrepreneur and Quebecer business man.
Georges Mathé was a French oncologist and immunologist. In November 1958, he performed the first successful allogeneic bone marrow transplant ever performed on unrelated human beings.
Claudio Carosino, MD was an Italian general practitioner and family physician, tutor and mentor engaged in rural medicine. Carosino was shot and killed by a patient while performing a house visit in the rural village of Roncole Verdi in Italy.
Alessandro Liberati was an Italian healthcare researcher and clinical epidemiologist, and founder of the Italian Cochrane Centre.
Paul Workman, is a British scientist noted for his work on the discovery and development of pharmaceutical agents in the field of oncology. He is President and CEO of The Institute of Cancer Research In London.
Gian Luigi Gessa is a professor of Neuropsychopharmacology at the University of Cagliari, where he has led for a long time the Department of Neurosciences. He is the leader of the Italian group that studies drug addiction. He also directed the research groups of the National Research Council.
Peter John Barnes, FRCP, FCCP, FMedSci, FRS is a British respiratory scientist and clinician, a specialist in the mechanisms and treatment of asthma and chronic obstructive pulmonary disease (COPD). He is currently Margeret Turner-Warwick Professor of Thoracic Medicine at the National Heart & Lung Institute, previous head of respiratory medicine at Imperial College and honorary consultant physician at the Royal Brompton Hospital London.
Cora Sternberg is an American medical oncologist at Weill Cornell Medicine and NewYork-Presbyterian Hospital, serving as a member of the Genitourinary (GU) Oncology Program. Dr. Sternberg facilitates the continued growth and development of clinical and translational research programs in GU malignancies, with a particular emphasis on expanding the overall research portfolio. As Clinical Director of the Englander Institute for Precision Medicine (EIPM), Dr. Sternberg will develop strategies to incorporate genomic sequencing and precision medicine throughout the Weill Cornell Medicine and NewYork-Presbyterian healthcare network, including Lower Manhattan, Brooklyn and Queens.
Kurt Hellmann was a Bavarian clinical pharmacologist best known for his discovery of the biologic activity of two important drugs: Razoxane & Dexrazoxane.
Filippo Drago is an Italian pharmacologist, neurologist and psychiatrist.
Harkishan Singh was Professor Emeritus at the Panjab University. He was a well recognized pharmaceutical academic, medicinal chemistry researcher and science historian. He had more than half a century experience in his respective fields to his credit. He worked at the Banaras Hindu University, University of Saugar, and the Panjab University in India, and abroad at the University of Maryland, University of Mississippi and the University of London.
Alberto Mantovani is an Italian physician and immunologist. He is Scientific Director of Istituto Clinico Humanitas, President and Founder of the Fondazione Humanitas per la Ricerca, and Professor of Pathology at the State University of Milan. He is known for his works in the roles of the immune system in the development of cancer. His research on tumor-associated macrophages established inflammation as one of the causes of cancer. He was the first to identify monocyte chemotactic protein - 1 / CCL2 in 1983, and PTX3 in 1997. His works revealed the existence of decoy receptors in cell-signalling. He has been the most cited scientist in Italy, and one of the ten most cited immunologists worldwide.
The Metastasis Research Society (MRS) is an international professional society dedicated to metastasis research and treatment. Headquartered in Tampa, Florida, the MRS was formed in 1974 as the E.O.R.T.C. Metastasis Club by Bavarian clinical pharmacologist Kurt Hellmann and Director of the Mario Negri Institute for Pharmacological Research Silvio Garattini. It took its current name in the mid-1980s, with its first international meeting as a formal society in 1984 in London.
Luciano Onder is an Italian journalist and science broadcaster, best known for presenting the shows Medicina 33 and TG5 Salute.